Company Overview
KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment. Its platform intends to utilize the KPI-012 clinical development dataset as a proof-of-concept validation environment, as well as the mesenchymal stem cell secretome (MSC-S) and persistent corneal epithelial defects (PCED) research for agentic workflows on trial data. The company serves biotechnology and pharmaceutical companies. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -99.86% |
| 6 Months: | -95.88% |
| 3 Months: | -76.51% |
| 1 Month: | -28.09% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)29.85 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 100.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | KALA KALA BIO, Inc. PHARMA | 0.54 | -0.06 | $10.44M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 1.39M | 2.06M | 1.45M | 1.18M | 1.07M | 833.00K | 2.22M | 2.24M | 3.27M | 3.05M | 3.07M | 1.37M | 2.10M | 420.00K | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -9.65M | -9.75M | -9.57M | -9.63M | -9.53M | -11.14M | -14.52M | -15.50M | -24.05M | -22.41M | -21.57M | - | -20.12M | -21.28M | -25.84M | - | -28.31M | -29.05M | -26.07M | -30.91M | -25.97M | -14.57M | -11.68M | -9.60M | -8.76M | -11.93M | -9.61M | -9.99M | -10.67M | -11.03M | -7.24M | -1.80M |
| Net Income | - | - | - | - | - | -11.30M | -14.62M | -15.60M | -25.39M | -23.82M | -23.18M | - | -21.95M | -23.31M | -27.95M | - | -30.41M | -36.50M | -28.13M | -32.94M | -28.11M | 29.07M | -14.46M | -10.41M | -8.70M | -11.81M | -9.58M | -8.95M | -8.95M | -11.15M | -7.56M | -1.62M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.49 | -0.57 | -21.41 | -22.18 | -18.92 | 19.25 | -6.99 | -4.36 | -3.41 | -4.20 | -3.16 | -1.93 | -70.49 | -1.71 | -1.07 | -0.14 |
| R&D Expense | 5.95M | 8.26M | 8.04M | 8.07M | 7.02M | 5.66M | 7.37M | 7.03M | 6.96M | 7.11M | 7.07M | - | 5.43M | 6.05M | 3.47M | - | 3.13M | 3.09M | 2.88M | 4.47M | 4.47M | 5.39M | 4.04M | 4.28M | 5.55M | 6.35M | 5.32M | 5.17M | 6.05M | 6.23M | 6.13M | 61.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 45.00K | 0 | 0 | - | 6.07M | 6.36M | 11.24M | 3.89M | 0 | 0 | 0 |
| Operating Income | -15.95M | -32.67M | -39.88M | -64.72M | -88.22M | -96.23M | -130.25M | -81.71M | -39.66M | -40.98M | -39.16M |
| Net Income | -16.68M | -33.17M | -42.21M | -66.74M | -94.35M | -104.33M | -142.60M | -44.82M | -42.20M | -38.51M | -26.98M |
| Diluted EPS | - | - | - | - | - | -1.99 | -108.32 | -29.48 | -17.35 | -10.15 | -3.31 |
| R&D Expense | 11.38M | 25.03M | 29.01M | 29.29M | 27.27M | 18.35M | - | - | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 46.33M | 116.55M | 220.97M | 154.32M | 221.61M | 139.43M | 86.82M | 55.95M | 55.48M | 9.49M |
| Total Equity | -40.72M | -56.66M | -87.76M | 89.68M | 104.98M | 29.69M | 100.00M | 16.80M | 18.97M | 7.50M | 12.33M | 7.00M |
| Cash & Equivalents | - | - | - | - | - | 85.45M | 77.26M | 92.14M | 70.50M | 50.90M | 51.18M | 7.56M |
| Long Term Debt | - | - | 9.10M | 11.99M | 70.23M | 71.18M | 72.24M | 78.93M | 37.94M | 34.19M | 20.10M | - |
| Total Liabilities | - | - | 15.70M | 26.87M | 115.99M | 124.63M | 121.61M | 122.62M | 67.85M | 48.45M | 43.15M | 2.49M |
| Current Liabilities | - | - | 5.55M | 14.87M | 17.01M | 24.77M | 22.23M | 37.42M | 25.68M | 8.35M | 16.96M | 2.49M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -15.09M | -27.35M | -34.10M | -54.12M | -92.72M | -90.69M | -108.23M | -78.91M | -27.93M | -29.38M | -31.99M |
| Investing Cash Flow | -252.00K | -153.00K | -480.00K | -1.58M | -1.33M | -78.21M | 70.80M | 62.72M | -429.00K | -208.00K | -15.00K |
| Financing Cash Flow | 10.48M | 67.21M | 103.70M | 124.10M | 8.98M | 160.63M | 42.55M | -7.94M | 8.51M | 29.88M | -11.62M |
| Capital Expenditure | -252.00K | -153.00K | -480.00K | -1.58M | -1.33M | - | - | - | - | - | - |
| Free Cash Flow | -15.34M | -27.50M | -34.58M | -55.70M | -94.06M | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -35,435.6% | - | - | - | -1,452.5% | -1,512.6% | -1,158.8% | -2,099.3% | - | - | - |
| Net Margin % | -37,071.1% | - | - | - | -1,553.3% | -1,639.8% | -1,268.7% | -1,151.6% | - | - | - |
| ROE % | 29.4% | 37.8% | -47.1% | -63.6% | -317.8% | -104.3% | -848.6% | -236.2% | -562.4% | -312.3% | -385.6% |
| ROCE % | - | -80.1% | -39.2% | -31.7% | -68.1% | -48.3% | -127.7% | -133.6% | -83.3% | -106.4% | -559.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 1.14% | 220.62K | $118.92K |
| 2 | Geode Capital Management, LLC | 0.75% | 145.15K | $78.24K |
| 3 | Vanguard Fiduciary Trust Co | 0.52% | 101.40K | $54.65K |
| 4 | Blackrock Inc. | 0.37% | 71.54K | $38.56K |
| 5 | Northern Trust Corporation | 0.22% | 41.61K | $22.43K |
| 6 | Qube Research & Technologies Ltd | 0.06% | 11.07K | $5.97K |
| 7 | Goldman Sachs Group Inc | 0.06% | 10.92K | $5.89K |
| 8 | UBS Group AG | 0.05% | 9.06K | $4.88K |
| 9 | Tower Research Capital LLC (TRC) | - | 616 | $332 |
| 10 | Barclays Plc | - | 608 | $327 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for KALA
Kala Bio Signs Exclusive U.S. Distribution Agreement for Virotek Ophthalmology Genetic Tests
Kala Bio, Inc. (NASDAQ:KALA) and Virotek Inc.
Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program
Agreement Grants Kala Exclusive U.S. Rights to Market and Distribute Virotek's Ophthalmology Genomic Testing ProgramARLINGTON, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Kala Bio, Inc. (Nasdaq: KALA) ("Kala") and Virotek Inc. ("Virotek") tod…
Kala Bio Targets Near-Term Revenue With Virotek Ophthalmology Genetic Testing Partnership
The proposed exclusive U. S. distribution agreement would give Kala a commercial opportunity in its established ophthalmology market while leaving Virotek responsible for laboratory operations and clinical reporting.…
Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program
ARLINGTON, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kala Bio, Inc. (Nasdaq: KALA) ("Kala") and Virotek Inc. ("Virotek"), a CLIA-registered precision health and clinical genomics company, today announced that they have entered into a letter…
KALA BIO Announces Reverse Stock Split
Common Stock Will Begin Trading on Split-Adjusted Basis on May 11, 2026ARLINGTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“KALA BIO” or the “Company”), today announced that it intends to effect a reverse stock…
Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine
Historic U.S. Executive Order Fast-Tracks Psychedelic Research Access; Landmark Policy Shift Strengthens the Outlook for KALA’s Client Red Light Holland and Positions Researgency.ai as the Dedicated AI Infrastructure Partner for the Global …
KALA — Frequently Asked Questions
What is the current share price of KALA BIO, Inc. (KALA)?
As of 2026-09-19 21:16 PDT, KALA BIO, Inc. (KALA) trades at $0.54 on NasdaqCM. Its 52-week range is $0.51 to $981.50.
What is the market capitalisation of KALA?
KALA BIO, Inc. (KALA) has a market capitalisation of $10.44M on NasdaqCM.
What is the P/E ratio of KALA?
KALA trades at a trailing price-to-earnings (P/E) ratio of -0.06. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.15.
Is KALA a good stock to buy?
This page provides a data-driven analysis of KALA BIO, Inc. (KALA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.